239 Littleton Road Westford, MA 01886
BioBehavioral Diagnostics Company (BioBDx) is a privately held company whose
mission is to develop, manufacture, and market proprietary diagnostic systems for the
quantitative assessment of behavioral disorders, including the measurement of medication
response and the prediction of therapeutic efficacy for a patient. The company’s lead
product, the McLean Motion and Attention Test for Attention Deficit Hyperactivity
Disorder (MMAT/ADHD™ System), is designed to enable clinicians to accurately make
office based diagnoses for ADHD, select the right class of medication, and measure
therapeutic efficacy of a given drug while determining an optimal dosage. The BioBDx
product portfolio includes ADHD diagnostic aid systems for children, adolescents, and
adults. The MMAT/ADHD™ System is currently FDA approved as an aid for the
diagnosis of ADHD.
Proceeds from the financing will be used to expand sales and marketing activities as well as to execute additional clinical work for the Quotient ADHD System.
Sevin Rosen Funds
Tullis Health Investors